Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

Jia Jia; Lili Mao; Jing Lin; Wenyu Li; Pei Yuan; Lei Guo; Jie Dai; Caili Li; Xue Bai; Zhongwu Li; Yu Chen; Jun Guo; Jianming Ying; Lu Si

doi:10.1007/s11684-023-1046-2

Front. Med. ›› 2024, Vol. 18 ›› Issue (3) : 565 -569. DOI: 10.1007/s11684-023-1046-2

LETTER TO FRONTIERS OF MEDICINE

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

Author information +

History +

PDF (949KB)

Cite this article

Download citation ▾

Jia Jia, Lili Mao, Jing Lin, Wenyu Li, Pei Yuan, Lei Guo, Jie Dai, Caili Li, Xue Bai, Zhongwu Li, Yu Chen, Jun Guo, Jianming Ying, Lu Si. Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy. Front. Med., 2024, 18(3): 565-569 DOI:10.1007/s11684-023-1046-2